ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Research Report 2024
Published Date: November 2024
|
Report Code: QYRE-Auto-34D18248
Home | Market Reports | Health| Pharmacy
Global Long acting Granulocyte Colony Stimulating Factor G CSF Market Research Report 2024
BUY CHAPTERS

Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Research Report 2024

Code: QYRE-Auto-34D18248
Report
November 2024
Pages:106
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Amgen Inc
Mylan NV
Kashiv BioSciences
Pfizer Inc
Fresenius Kabi
Coherus BioSciences
Sandoz Inc
Italfarmaco SPA
Evive Biotech
Chugai Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Amoytop Biotech
Qilu Pharmaceutical
CSPC Baike Biopharma
SL PHARM
Lunan Pharmaceutical

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market

The global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is a modified form of G-CSF designed to stimulate sustained production and release of neutrophils, a type of white blood cell vital for infection defense, over an extended period. Unlike short-acting G-CSF, which requires daily injections, long-acting G-CSF, such as pegfilgrastim, incorporates a polyethylene glycol (PEG) molecule that slows its breakdown and clearance from the body, allowing for prolonged therapeutic effects and reduced dosing frequency, typically once per chemotherapy cycle.
North American market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) include Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, Coherus BioSciences, Sandoz, Italfarmaco SpA, Evive Biotech, Chugai Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-acting Granulocyte-Colony Stimulating Factor (G-CSF).
The Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Report

Report Metric Details
Report Name Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market
Segment by Type
  • Pegfilgrastim
  • Lenograstim
  • Other
Segment by Application
  • Hospital and Clinic
  • Pharmacy
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, Coherus BioSciences, Sandoz, Italfarmaco SpA, Evive Biotech, Chugai Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Amoytop Biotech, Qilu Pharmaceutical, CSPC Baike Biopharma, SL Pharm, Lunan Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market report?

Ans: The main players in the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market are Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, Coherus BioSciences, Sandoz, Italfarmaco SpA, Evive Biotech, Chugai Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Amoytop Biotech, Qilu Pharmaceutical, CSPC Baike Biopharma, SL Pharm, Lunan Pharmaceutical

What are the Application segmentation covered in the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market report?

Ans: The Applications covered in the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market report are Hospital and Clinic, Pharmacy, Other

What are the Type segmentation covered in the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market report?

Ans: The Types covered in the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market report are Pegfilgrastim, Lenograstim, Other

Recommended Reports

G-CSF & Related Therapies

Stem Cell & Hematology

Hematologic Disorders Treatment

1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Overview
1.1 Product Definition
1.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Type
1.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value Comparison by Type (2024-2030)
1.2.2 Pegfilgrastim
1.2.3 Lenograstim
1.2.4 Other
1.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Application
1.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value by Application (2024-2030)
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size Estimates and Forecasts
1.4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue 2019-2030
1.4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales 2019-2030
1.4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Competition by Manufacturers
2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Product Type & Application
2.7 Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Date of Enter into This Industry
2.8 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Competitive Situation and Trends
2.8.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Players Market Share by Revenue
2.8.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Scenario by Region
3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2019-2030
3.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2019-2024
3.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2025-2030
3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2019-2030
3.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2019-2024
3.3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2025-2030
3.4 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
3.4.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2019-2030)
3.4.3 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
3.5.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2019-2030)
3.5.3 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Region
3.6.1 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2019-2030)
3.6.3 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
3.7.1 Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2019-2030)
3.7.3 Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
3.8.1 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2019-2030)
4.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2019-2024)
4.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2025-2030)
4.1.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2019-2030)
4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2019-2030)
4.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2019-2024)
4.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2025-2030)
4.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2019-2030)
4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2019-2030)
5.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2019-2024)
5.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2025-2030)
5.1.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2019-2030)
5.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2019-2030)
5.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2019-2024)
5.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2025-2030)
5.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2019-2030)
5.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Company Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Mylan
6.2.1 Mylan Company Information
6.2.2 Mylan Description and Business Overview
6.2.3 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.2.5 Mylan Recent Developments/Updates
6.3 Kashiv BioSciences
6.3.1 Kashiv BioSciences Company Information
6.3.2 Kashiv BioSciences Description and Business Overview
6.3.3 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.3.5 Kashiv BioSciences Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Fresenius Kabi
6.5.1 Fresenius Kabi Company Information
6.5.2 Fresenius Kabi Description and Business Overview
6.5.3 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.5.5 Fresenius Kabi Recent Developments/Updates
6.6 Coherus BioSciences
6.6.1 Coherus BioSciences Company Information
6.6.2 Coherus BioSciences Description and Business Overview
6.6.3 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.6.5 Coherus BioSciences Recent Developments/Updates
6.7 Sandoz
6.7.1 Sandoz Company Information
6.7.2 Sandoz Description and Business Overview
6.7.3 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.7.5 Sandoz Recent Developments/Updates
6.8 Italfarmaco SpA
6.8.1 Italfarmaco SpA Company Information
6.8.2 Italfarmaco SpA Description and Business Overview
6.8.3 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.8.5 Italfarmaco SpA Recent Developments/Updates
6.9 Evive Biotech
6.9.1 Evive Biotech Company Information
6.9.2 Evive Biotech Description and Business Overview
6.9.3 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.9.5 Evive Biotech Recent Developments/Updates
6.10 Chugai Pharmaceutical
6.10.1 Chugai Pharmaceutical Company Information
6.10.2 Chugai Pharmaceutical Description and Business Overview
6.10.3 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.10.5 Chugai Pharmaceutical Recent Developments/Updates
6.11 Jiangsu Hengrui Pharmaceuticals
6.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.11.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.11.3 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.12 Amoytop Biotech
6.12.1 Amoytop Biotech Company Information
6.12.2 Amoytop Biotech Description and Business Overview
6.12.3 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.12.5 Amoytop Biotech Recent Developments/Updates
6.13 Qilu Pharmaceutical
6.13.1 Qilu Pharmaceutical Company Information
6.13.2 Qilu Pharmaceutical Description and Business Overview
6.13.3 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.13.5 Qilu Pharmaceutical Recent Developments/Updates
6.14 CSPC Baike Biopharma
6.14.1 CSPC Baike Biopharma Company Information
6.14.2 CSPC Baike Biopharma Description and Business Overview
6.14.3 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.14.4 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.14.5 CSPC Baike Biopharma Recent Developments/Updates
6.15 SL Pharm
6.15.1 SL Pharm Company Information
6.15.2 SL Pharm Description and Business Overview
6.15.3 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.15.4 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.15.5 SL Pharm Recent Developments/Updates
6.16 Lunan Pharmaceutical
6.16.1 Lunan Pharmaceutical Company Information
6.16.2 Lunan Pharmaceutical Description and Business Overview
6.16.3 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.16.5 Lunan Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Chain Analysis
7.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Production Mode & Process
7.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Marketing
7.4.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Channels
7.4.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors
7.5 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customers
8 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Dynamics
8.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends
8.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Drivers
8.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Challenges
8.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Amgen Inc
Mylan NV
Kashiv BioSciences
Pfizer Inc
Fresenius Kabi
Coherus BioSciences
Sandoz Inc
Italfarmaco SPA
Evive Biotech
Chugai Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Amoytop Biotech
Qilu Pharmaceutical
CSPC Baike Biopharma
SL PHARM
Lunan Pharmaceutical
List of Tables
 Table 1. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Product Type & Application
 Table 12. Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2019-2024) & (K Units)
 Table 18. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2019-2024)
 Table 19. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2025-2030) & (K Units)
 Table 20. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2025-2030)
 Table 21. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2019-2024)
 Table 23. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2025-2030)
 Table 25. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2019-2024) & (K Units)
 Table 27. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2025-2030) & (K Units)
 Table 28. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2019-2024) & (K Units)
 Table 32. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2025-2030) & (K Units)
 Table 33. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) by Type (2019-2024)
 Table 51. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) by Type (2025-2030)
 Table 52. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2019-2024)
 Table 53. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2025-2030)
 Table 54. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2019-2024)
 Table 57. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2025-2030)
 Table 58. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Type (2019-2024)
 Table 59. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Type (2025-2030)
 Table 60. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) by Application (2019-2024)
 Table 61. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) by Application (2025-2030)
 Table 62. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2019-2024)
 Table 63. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2025-2030)
 Table 64. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2019-2024)
 Table 67. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2025-2030)
 Table 68. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Application (2019-2024)
 Table 69. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Application (2025-2030)
 Table 70. Amgen Company Information
 Table 71. Amgen Description and Business Overview
 Table 72. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 74. Amgen Recent Developments/Updates
 Table 75. Mylan Company Information
 Table 76. Mylan Description and Business Overview
 Table 77. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 79. Mylan Recent Developments/Updates
 Table 80. Kashiv BioSciences Company Information
 Table 81. Kashiv BioSciences Description and Business Overview
 Table 82. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 84. Kashiv BioSciences Recent Developments/Updates
 Table 85. Pfizer Company Information
 Table 86. Pfizer Description and Business Overview
 Table 87. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 89. Pfizer Recent Developments/Updates
 Table 90. Fresenius Kabi Company Information
 Table 91. Fresenius Kabi Description and Business Overview
 Table 92. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 94. Fresenius Kabi Recent Developments/Updates
 Table 95. Coherus BioSciences Company Information
 Table 96. Coherus BioSciences Description and Business Overview
 Table 97. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 99. Coherus BioSciences Recent Developments/Updates
 Table 100. Sandoz Company Information
 Table 101. Sandoz Description and Business Overview
 Table 102. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 104. Sandoz Recent Developments/Updates
 Table 105. Italfarmaco SpA Company Information
 Table 106. Italfarmaco SpA Description and Business Overview
 Table 107. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 109. Italfarmaco SpA Recent Developments/Updates
 Table 110. Evive Biotech Company Information
 Table 111. Evive Biotech Description and Business Overview
 Table 112. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 114. Evive Biotech Recent Developments/Updates
 Table 115. Chugai Pharmaceutical Company Information
 Table 116. Chugai Pharmaceutical Description and Business Overview
 Table 117. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 119. Chugai Pharmaceutical Recent Developments/Updates
 Table 120. Jiangsu Hengrui Pharmaceuticals Company Information
 Table 121. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
 Table 122. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 123. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 124. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
 Table 125. Amoytop Biotech Company Information
 Table 126. Amoytop Biotech Description and Business Overview
 Table 127. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 128. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 129. Amoytop Biotech Recent Developments/Updates
 Table 130. Qilu Pharmaceutical Company Information
 Table 131. Qilu Pharmaceutical Description and Business Overview
 Table 132. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 133. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 134. Qilu Pharmaceutical Recent Developments/Updates
 Table 135. CSPC Baike Biopharma Company Information
 Table 136. CSPC Baike Biopharma Description and Business Overview
 Table 137. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 138. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 139. CSPC Baike Biopharma Recent Developments/Updates
 Table 140. SL Pharm Company Information
 Table 141. SL Pharm Description and Business Overview
 Table 142. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 143. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 144. SL Pharm Recent Developments/Updates
 Table 145. Lunan Pharmaceutical Company Information
 Table 146. Lunan Pharmaceutical Description and Business Overview
 Table 147. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 148. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
 Table 149. Lunan Pharmaceutical Recent Developments/Updates
 Table 150. Key Raw Materials Lists
 Table 151. Raw Materials Key Suppliers Lists
 Table 152. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors List
 Table 153. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customers List
 Table 154. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Trends
 Table 155. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Drivers
 Table 156. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Challenges
 Table 157. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Restraints
 Table 158. Research Programs/Design for This Report
 Table 159. Key Data Information from Secondary Sources
 Table 160. Key Data Information from Primary Sources
 Table 161. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
 Figure 2. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share by Type: 2023 & 2030
 Figure 4. Pegfilgrastim Product Picture
 Figure 5. Lenograstim Product Picture
 Figure 6. Other Product Picture
 Figure 7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value by Application (2024-2030) & (US$ Million)
 Figure 8. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share by Application: 2023 & 2030
 Figure 9. Hospital and Clinic
 Figure 10. Pharmacy
 Figure 11. Other
 Figure 12. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 13. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size (2019-2030) & (US$ Million)
 Figure 14. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (2019-2030) & (K Units)
 Figure 15. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price (US$/Unit) & (2019-2030)
 Figure 16. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Report Years Considered
 Figure 17. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Share by Manufacturers in 2023
 Figure 18. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Manufacturers in 2023
 Figure 19. Global 5 and 10 Largest Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Players: Market Share by Revenue in Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in 2023
 Figure 20. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 21. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 22. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2019-2030)
 Figure 23. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2019-2030)
 Figure 24. United States Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 25. Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 26. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2019-2030)
 Figure 27. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2019-2030)
 Figure 28. Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 29. France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. U.K. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 33. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2019-2030)
 Figure 34. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2019-2030)
 Figure 35. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. China Taiwan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2019-2030)
 Figure 43. Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Argentina Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Colombia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 47. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2019-2030)
 Figure 48. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2019-2030)
 Figure 49. Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. Saudi Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. UAE Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 52. Global Sales Market Share of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Type (2019-2030)
 Figure 53. Global Revenue Market Share of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Type (2019-2030)
 Figure 54. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Type (2019-2030)
 Figure 55. Global Sales Market Share of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Application (2019-2030)
 Figure 56. Global Revenue Market Share of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Application (2019-2030)
 Figure 57. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Application (2019-2030)
 Figure 58. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain
 Figure 59. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Production Process
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Granulocyte Colony Stimulating Factor G CSF Market Research Report 2024
Granulocyte Colony Stimulating Factor G CSF Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Granulocyte Macrophage Colony Stimulating Factor GM CSF Market Research Report 2024
Global PEGylated Granulocyte Colony Stimulating Factor Market Research Report 2024
Global Human Granulocyte Macrophage Colony stimulating Factor for Injection Market Research Report 2024
Global Human Granulocyte Colony Stimulating Factor for Injection Market Research Report 2024
Global Stem Cell Growth Factors Market Research Report 2025
Global Recombinant Human Granulocyte Colony Stimulating Factor Injection rhG CSF Market Research Report 2025
Global PEG rhG CSF Market Research Report 2025
Global Recombinant Human Granulocyte Colony Stimulating Market Insights Forecast to 2030
Global Stem Cell Cytokines Market Research Report 2024
Global Stromal Cell Derived Factor 1 Market Research Report 2024
Global Recombinant Human GM CSF for Injection Market Research Report 2024
Global Filgrastim and Biosimilars Market Research Report 2024
Global Fibroblast Growth Factors FGF Market Research Report 2025
Leukemia Inhibitory Factor LIF Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Filgrastim Market Insights Forecast to 2030
Global Cell Culture Products Market Research Report 2024
Global Cancer Stem Cells CSCs Market Research Report 2024
Global Myelodysplastic Syndrome Market Research Report 2024

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions